Square of Spain - National museum of Barcelona with fountain at summer day, Spain, retro toned

Researchers at the Spanish Centro Nacional de Investigaciones Cardiovasculares Carlos III, directed by Valent?n Fuster, have investigated how different sub-types of essential immune-response cells called CD8+ T lymphocytes cooperate to mount a stronger anti-tumor response. [1]

The results show that generation of an optimal immune response to cancer requires cooperation between two types of memory T cell–one circulating in the blood and the other resident in tissues – that can be reactivated with current immunotherapy strategies.

These results, published today in Nature Communications, have the potential to improve current cancer immunotherapy strategies, especially in relation to the prevention of metastasis – the dissemination of the tumor to organs distant from the site of origin.

Immunotherapy, the use of the immune system to fight cancer, is revolutionizing treatment of this disease, and was selected by the prestigious journal Science as the major scientific advance of 2013.

Photo 1.0: Metastases (black regions) in the lungs of wild type (WT) mice and mice lacking DC1 dendritic cells (Batf3-/-), showing that DC1 dendritic cells are required for efficient immunotherapy upon vaccination with tumor antigens.

“Cancer escapes the control of the immune system because the cytotoxic T lymphocytes that could recognize and eliminate tumor cells are inhibited. Current immunotherapy is based the reactivation of these T lymphocytes. However, little is known about how they can be generated more effectively, and in particular how immune memory can be triggered to prevent the development of tumors and metastasis,” explained study leader David Sancho.

Advertisement #3

The CNIC research team generated cytotoxic memory T cells specifically targeting cancer by using different methods for vaccination with tumor antigens. Depending on the vaccination method, the memory T lymphocytes obtained circulate between the blood and tissues or reside in the tissues and do not recirculate. Tissue-resident memory T cells were known to be more efficient at fighting viral reinfection, but their contribution to anti-tumor immunity was unknown until now.

Describing the study, first author Michel Enamorado explains how the team “compared the efficiency of anti-tumor immunity conferred by each type of memory T cell, and we found that the circulating and tissue-resident memory cells cooperate to generate the optimal response. Tissue-resident memory cells generate an alert state that attracts and reactivates the circulating memory cells, resulting in a faster and more effective immune response.”

Photo 2.0: The CNIC research team. From left to right: Andr?s Hidalgo, David Sancho, Sarai Mart?nez-Cano, Salvador Iborra, Elena Priego, Michel Enamorado, and Juan Antonio Quintana.

Adoptive transfer of T lymphocytes
Another cancer immunotherapy approach already used in patients is the adoptive transfer of tumor-targeting T cells. The authors demonstrate that transferred circulating memory T cells are able to convert themselves into resident memory cells in the context of infection and cancer. Moreover, the efficiency of immunotherapy was further increased by combining this adoptive transfer with the current clinical strategy of reactivating the T cell antitumor response with antibodies to the receptor PD-1. The authors also found that reactivation of the anti-tumor response in cytotoxic memory T cells requires the DC1 subtype of dendritic cells.

The study suggests that an optimal anti-tumor immune response requires the generation of both circulating and tissue-resident T cell memory. Both memory T cells subtypes can be reactivated with current immunotherapy treatments, and reactivation of both requires DC1 dendritic cells. Cancer immunotherapy is not simply a treatment that can effectively promote the rejection of primary tumors; above all, it is a fundamental tool for impeding metastasis after surgery to remove the primary tumor.

The CNIC, recognized by the Spanish government as a Severo Ochoa center of excellence, is financed through a pioneering public-private partnership between the government (through the Carlos III Institute of Health) and the Pro-CNIC Foundation, which brings together 14 of the most important Spanish private companies.


Last editorial review: July 17, 2017

Featured Image:National museum of Barcelona with fountain at summer day, Spain, retro toned Courtesy: ? 2017 Fotolia. Used with permission. Photo 1.0: Metastases (black regions) in the lungs of wild type (WT) mice and mice lacking DC1 dendritic cells (Batf3-/-), showing that DC1 dendritic cells are required for efficient immunotherapy upon vaccination with tumor antigens. Courtesy: ? 2017 CNIC – Centro Nacional de Investigaciones Cardiovasculares Carlos III.? Photo 2.0: The CNIC research team. From left to right: Andr?s Hidalgo, David Sancho, Sarai Mart?nez-Cano, Salvador Iborra, Elena Priego, Michel Enamorado, and Juan Antonio Quintana. Courtesy: ? 2017 CNIC – Centro Nacional de Investigaciones Cardiovasculares Carlos III.

Copyright ? 2017 Sunvalley Communication, LLC. All rights reserved. Republication or redistribution of Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of Sunvalley Communication. Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco?Zine, Oncozine and The Onco?Zine Brief are registered trademarks and trademarks of Sunvalley Communication around the world.

Advertisement #5